Evolus Strategic Advantage and Growth
LOVVOLUS
EXPANDING OUR FOOTPRINT:
•
UNITED KINGDOM AND E.U.
Evolus is expanding its filler offering into the
United Kingdom and E.U. with EstymeⓇ
Exclusive distribution agreement with
Symatese
SYMATESE
"NUCEIVA
prabotulinumtoxinA
injection
Estyme
$900M
FILLERS
•
E.U. regulatory approvals anticipated in
second half 2024
$1.8B
•
Doubles our addressable international
market to $1.8B1
·
Remain fully funded to profitability2
•
Evolus will license NuceivaⓇ to Symatese for distribution
in France, marking the fifth European market that
Evolus has entered
$900M
1.
Source: Medical Insights Dermal Filler Market Study, March 2023 (www.miinews.com) and Aesthetic Injectables | Market Insights |
Europe 2024 2023 Clarivate
2.
Please refer to the "Use of Non-GAAP Financial Measures" on slide 3
NEUROTOXINS
De
00
8View entire presentation